Navigation Links
BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX® for Treatment of Peyronie's Disease
Date:10/12/2010

t has developed injectable collagenase for eleven clinical indications, three of which include: Dupuytren's contracture; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has gained approval of XIAFLEX in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAFLEX in Europe. More information about the Company may be found on its website at www.biospecifics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, its expected revenue growth, and any other statements containing the words "believes," "expects," "anticipates," "plans," "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause its actual results to differ materially from those indicated by such forward-looking statements, including the statements made by BioSpecifics and by its partner Auxilium regarding the ability to obtain regulatory approval of XIAFLEX in the U.S. for Peyronie's disease; and other risk factors identified in the Company's Form 10-K for the year ended December 31, 2009 filed with the SEC. There may be additional risks that BioSpecifics does not currently know or that BioSpecifics currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect; therefore, any such factors or forward-looking statements should not be relied upon.
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
2. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
3. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
4. BioSpecifics Technologies Corp. Announces FDA Approval of XIAFLEX(TM) for Treatment of Dupuytrens Contracture
5. BioSpecifics Technologies Corp. to Present at the Piper Jaffray 21st Annual Health Care Conference
6. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
7. BioSpecifics Technologies Corp. to Present at Cowen and Company 30th Annual Health Care Conference
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2009 Financial Results on March 10, 2010
9. BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytrens Contracture
10. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results
11. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2010 Financial Results on May 7, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 E-QURE Corp (OTCQB: ... present live at VirtualInvestorConferences.com on July 9, 2015. ... http://tinyurl.com/e-qure-presentation This will be ... to ask the company questions in real-time - both ... "virtual trade booth." If attendees are not able to ...
(Date:7/6/2015)... MORRISTOWN, N.J. , July 6, 2015 /PRNewswire/ ... focused on developing novel therapeutics that target inflammation ... Bill Bradford , M.D., PhD, as Chief Medical ... the company,s clinical development strategy and programs, which ... and other inflammatory and fibrotic conditions.  Bill is ...
(Date:7/6/2015)... July 6, 2015  Impax Laboratories, Inc. (NASDAQ: ... Ph.D. has resigned from the Company,s Board of Directors ... was a co-founder of Impax in 1995 and served ... October 2006 until April 2014. Logo - ... Impax,s President and Chief Executive Officer stated, "We wish ...
Breaking Medicine Technology:E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9 2Moerae Matrix, Inc. (Moerae) Appoints Bill Bradford, M.D., PhD, as Chief Medical Officer 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 3Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 4Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 5
... Berg Pharma, a Boston based pharmaceutical company presented novel ... metabolism at the 103rd Annual AACR meeting.  The company ... that dealt with endothelial cell biology relative to tumor ... cancer therapy, synergy of BPM 31510, Berg,s lead oncology ...
... April 4, 2012 Zimmer Holdings, Inc. (NYSE: ... sales and earnings conference call will be broadcast live over ... Eastern Time.  A news release detailing the quarterly results will ... of the conference call. The live audio ...
Cached Medicine Technology:Berg Pharma Presents Key Findings in Cancer Systems Biology and Mitochondrial Metabolism at AACR Meeting 2Berg Pharma Presents Key Findings in Cancer Systems Biology and Mitochondrial Metabolism at AACR Meeting 3Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2012 Results 2
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... The Path ... look into the economic transformation associated with the U.S. economy over the past 40 ... associated with its use. In many ways, the book is a time capsule that ...
(Date:7/5/2015)... ... July 05, 2015 , ... Women's Excellence in Wellness, powered ... These classes are geared towards families that want their children to stay active ... , The fitness class will take place TUESDAYS at 4:30pm. Questions? Call 248-601-6683. ...
(Date:7/5/2015)... ... July 05, 2015 , ... Doctors at the Swedish Cancer Institute in ... one day change the outlook for people with pleural mesothelioma. Surviving Mesothelioma has just ... Researchers report that five mesothelioma patients treated with 25Gy of radiation over five days ...
(Date:7/4/2015)... ... ... Chronic Neck Pain. Neck pain is no small problem. NIH ... Another 19% suffer from head, migraine, or facial pain, in some cases related to ... workers must deal with neck pain. Strategies for mitigating neck pain range ...
(Date:7/3/2015)... ... ... Harvest Hope Food Bank will hopefully be getting a large donation of canned food ... of Greenville SC are making it their mission to collect as many canned items as ... donations from the public as well. As part of the canned food drive, these local ...
Breaking Medicine News(10 mins):Health News:New Book Brings Reveals The Repercussions Associated With The Global Economy 2Health News:New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma 2Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 2Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 3
... Blue Cross and Blue Shield of Georgia (BCBSGA) announced today ... H1N1 (swine flu) vaccine when it becomes commercially available to ... members whose benefit plans provide coverage for vaccines. , ... flu vaccine administration for those whose health plans offer vaccine ...
... Scientists at Leeds and Bradford have discovered a unique ,DNA ... that unlocks an egg,s fertility and triggers new life. ... of Leeds, in collaboration with Dr Martin Brinkworth at the ... signature that can only be recognised by an egg from ...
... , , ANAHEIM, Calif., Aug. ... advanced entertainment and digital display technology options, LG Electronics has ... patient rooms - with its new "HealthView"(TM) series ... For patients, families and doctors alike, HealthView and other ...
... SILVER SPRING, Md., Aug. 3 Four simple questions ... ongoing couples therapy can greatly increase chances for reconciliation and ... clinical trial with couples to date, it shows that divorce ... were 46.2 percent less than that of couples who received ...
... , , PHOENIX, Aug. ... in stabilized rice bran (SRB), nutrient research and technology, today announced three ... the Company. , , Leo Gingras, Chief Operating Officer ... 2012. Gingras joined NutraCea in 2007 as COO, after 18 years ...
... , , ... Inc. ("Zogenix"), a privately held pharmaceutical company and Astellas ... agreement for Sumavel DosePro (sumatriptan injection) needle-free delivery system. ... and is a first-of-its-kind needle-free delivery system for subcutaneous ...
Cached Medicine News:Health News:BCBSGA Announces Decision to Cover H1N1 Vaccine Administration 2Health News:Unlocking the key to human fertility 2Health News:Unlocking the key to human fertility 3Health News:LG Electronics Introduces New Flat-Panel HDTVs Designed Specifically for Long-Term Care Facilities 2Health News:LG Electronics Introduces New Flat-Panel HDTVs Designed Specifically for Long-Term Care Facilities 3Health News:LG Electronics Introduces New Flat-Panel HDTVs Designed Specifically for Long-Term Care Facilities 4Health News:Therapy Technique Cuts Divorce/Separation Rate By Nearly 50 Percent 2Health News:NutraCea Announces Additions to Management Team; Chief Operating Officer Extends Employment Contract 2Health News:NutraCea Announces Additions to Management Team; Chief Operating Officer Extends Employment Contract 3Health News:NutraCea Announces Additions to Management Team; Chief Operating Officer Extends Employment Contract 4Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 2Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 3Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 4
... Used for catheter positioning and exchange in ... the wire guide coils allows utilization of ... smooth transition to a very flexible tip. ... is the most rigid coiled wire guide ...
Supplied sterile in peel-open packages. Intended for one-time use....
... Used as an initial access wire into ... prior to an endourology procedure. The mandril type ... that of a .035 inch (0.89 mm) diameter ... guide is of spring coil construction over the ...
Used for percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: